Pulse Biosciences (NASDAQ:PLSE) Shares Down 6.6% – Here’s Why

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares were down 6.6% on Thursday . The company traded as low as $23.24 and last traded at $22.93. Approximately 44,313 shares changed hands during trading, a decline of 68% from the average daily volume of 139,864 shares. The stock had previously closed at $24.56.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Stock Down 0.0 %

The firm has a fifty day moving average price of $18.85 and a 200-day moving average price of $17.92.

Insider Buying and Selling at Pulse Biosciences

In related news, Director Robert W. Duggan purchased 55,256 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several hedge funds have recently made changes to their positions in PLSE. Charles Schwab Investment Management Inc. grew its stake in shares of Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock worth $2,598,000 after acquiring an additional 1,092 shares during the period. SG Americas Securities LLC bought a new position in Pulse Biosciences during the fourth quarter worth about $193,000. Bender Robert & Associates bought a new position in Pulse Biosciences during the fourth quarter worth about $202,000. Creative Planning increased its stake in shares of Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Pulse Biosciences in the fourth quarter valued at approximately $311,000. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.